Search for: "Hospira"
Results 41 - 60
of 487
Sort by Relevance
|
Sort by Date
26 Mar 2020, 8:32 am
Cir. 2020) Hospira, Samsung Bioepis, Celltrion, and Pfizer each filed one or more inter partes review (IPR) petitions challenging Genentech breast-cancer slow-down patents: US7846441 and US7892549. [read post]
26 Mar 2020, 7:00 am
Hospira Inc. v. [read post]
17 Mar 2020, 1:32 pm
The U.S. [read post]
5 Mar 2020, 6:05 am
Hospira v. [read post]
3 Mar 2020, 4:03 am
Hospira, Inc., 881 F.3d 1347, 1350 (Fed. [read post]
3 Mar 2020, 4:00 am
” In January, the Federal Court of Appeal, in a decision written by Justice Locke, said in Hospira Healthcare Corporation v. [read post]
27 Feb 2020, 8:21 am
Hospira, Inc. v. [read post]
15 Jan 2020, 9:28 pm
Hospira, Inc. [read post]
14 Jan 2020, 9:10 pm
This tendency was most recently illustrated in the Federal Circuit's decision in Hospira, Inc. v. [read post]
14 Jan 2020, 11:14 am
Hospira, Inc., -- F. [read post]
10 Jan 2020, 9:15 am
The ‘106 patent, owned by Hospira, Inc. [read post]
10 Jan 2020, 9:15 am
The ‘106 patent, owned by Hospira, Inc. [read post]
9 Jan 2020, 4:50 pm
Hospira, Inc. v. [read post]
18 Dec 2019, 9:59 pm
By Kevin E. [read post]
17 Dec 2019, 4:15 am
Patent No. 5,856,298 (the ‘298 patent) belonging to Amgen was infringed by Hospira and not invalid; 2) 14 batches of drug substance for Hospira’s erythropoietin biosimilar drug product were not covered by the Safe Harbor provision of 35 USC § 271(e)(1); and 3) Amgen had proven that it was entitled to a jury verdict of $70 million in... [read post]
17 Dec 2019, 4:15 am
Patent No. 5,856,298 (the ‘298 patent) belonging to Amgen was infringed by Hospira and not invalid; 2) 14 batches of drug substance for Hospira’s erythropoietin biosimilar drug product were not covered by the Safe Harbor provision of 35 USC § 271(e)(1); and 3) Amgen had proven that it was entitled to a jury verdict of $70 million in damages. [read post]
22 Nov 2019, 10:32 am
Hospira, Inc., 933 F.3d 1320 (Fed. [read post]
20 Aug 2019, 2:05 am
Hospira, Inc., the Federal Circuit found the claim amendments at issue to be “tangential” to the “equivalent” at issue, and upheld findings of infringement. [read post]
12 Aug 2019, 9:54 pm
Hospira, Inc. and Eli Lilly & Co. v. [read post]
9 Aug 2019, 8:54 am
Hospira, Inc. [read post]
